드러그인포 약품요약정보 - 올리클리노멜N4-550E주사1500mL

허가정보

항목

내용

청구코드(KD코드)
비급여점검코드
상한금액

646600860[E04270482] [보험코드에 따른 약품기본정보 직접조회]
\0 원/1500ml/백(2015.11.01)(현재약가)
\37,400 원/1500ml/백(2014.03.01)(변경전약가)
[상병코드조회]
[질병코드조회]

빠른조회


요약정보	[효능] [용법] [금기] [신중투여] [이상반응]

상세정보	[효능] [용법] [경고] [금기] [신중투여] [이상반응] [일반주의] [상호작용] [임산부] [수유부] [소아] [고령자] [신장애환자] [간장애환자] [적용주의] [과량투여] [임상검사치] [보관] [기타]

제품성상

2개의 격막에 의해 3개의 공간으로 분리된 하나의 투명한 수액용 플라스틱 백에 A, B, C액이 각각 충전되어 있다. A액은 백색의 유화액으로서 유동성이 있는 액상 제제이고 B액과 C액은 미황색의 투명한 액제이다. [제형정보 확인]

포장·유통단위

1500ml/bag

포장·코드단위

약품규격	단위	포장형태	대표코드	표준코드	비고
1500밀리리터	1 개	백	8806466008602	8806466008619

주성분코드

475400BIJ [동일한 주성분코드를 가진 오리지날 또는 제네릭 의약품 조회]

허가사항 원문조회

[허가사항 원문조회]

효능효과

[적응증 별 검색]

경구 또는 위장관 영양보급이 불가능 또는 불충분하거나 또는 제한되어 경정맥 영양공급을 실시해야 하는 환자들에게 수분, 전해질, 아미노산 및 칼로리 보급

용법용량

* 절대 임의복용하지 마시고 반드시 의사 또는 약사와 상담하시기 바랍니다.

[처방약어]
[주성분코드:475300BIJ 에 따른 심사지침열람]
이 약은 중심정맥 또는 말초정맥으로 투여한다.
환자의 상태와 열량소비 그리고 대사 요구량에 따라 용량을 결정한다. 임상적 필요에 따라 계속하여 투여할 수 있다.
○성인

-권장량 : 질소로서 1일 체중 kg 당 0.16 g(아미노산으로서 1일 체중 kg 당 1 g)～0.35 g(아미노산으로서 1일 체중 kg 당 2 g)

-환자의 영양상태와 이화작용의 정도에 따라 필요한 열량은 1일 체중 kg 당 25～40 kcal이다.

-1일 최대투여량 : 환자의 체중 kg당 40 mL (체중 kg 당 아미노산 0.88 g, 포도당 3.2 g, 지방 0.8 g에 해당함)

-투여속도 : 총 투여량, 투여되는 최종 혼합액의 특성, 1일 투여량, 투여시간 등을 고려하여 결정한다. 일반적으로 투여시작 1시간 동안 점차적으로 투여속도를 증가시킨다. 12～24시간에 걸쳐서 투여하는 것이 바람직하다.
최대 주입속도는 3 mL/kg/시간을 초과하지 않도록 한다(시간당 아미노산 0.066 g/kg, 포도당 0.24 g/kg, 지방 0.06 g/kg 해당함).
이 약은 전해질을 함유하고 있으나, 비타민, 미량원소는 함유하고 있지 않다. 따라서 필요에 따라, 전해질, 비타민, 미량원소를 첨가하여 투여할 수 있다.

-전해질
이 약에 전해질을 추가할 경우, 어떠한 경우에도 최종 전해질 농도가 다음 농도를 초과해서는 안 된다.
․나트륨: 150 mmol/L
․칼륨: 150 mmol/L
․마그네슘: 5.60 mmol/L
․칼슘: 5 mmol/L
-미량원소 및 비타민
성인에서 권장되는 처방이 있을 경우 그것을 적용한다.

[BMI지수 계산] [Body Surface Area 계산] [Cockcroft-Gault GFR 계산] [MDRD GFR 계산]

금기

1) 조산아, 신생아 및 영아
2) 달걀, 대두유 단백, 또는 이 약의 성분에 알려진 과민반응을 나타내는 환자
3) 혈액투석, 혈액여과 또는 혈액투석여과를 하지 못하는 신장애 환자
4) 중증 간질환 환자
5) 선천성 아미노산 대사 이상 환자
6) 중증 혈액응고 장애 환자
7) 고지혈증 환자
8) 시간당 인슐린 6단위 이상 필요한 고혈당증 환자
9) 이 약에 함유된 전해질의 혈청학적 수치가 병적으로 높은 환자
10) 수액요법의 일반적 금기 : 급성 폐부종, 수분 과다 공급, 대상부전성 심부전, 저장성 탈수

11) 다음과 같은 불안정 상태 : 중증 외상 후 상태, 대상부전성 당뇨, 순환기계 쇽, 발작, 급성 심근경색, 대사성 산증, 고젖산혈증 환자, 중증 패혈증, 고장성 혼수 등

12) 간성혼수 또는 간성혼수의 염려가 있는 환자
13) 혈구포식세포 증후군 환자
14) 부신기능부전증 환자
15) 중증 패혈증과 같은 중증 지방 대사 장애 환자, 지방 색전증 환자

신중투여

1) 신부전, 췌장염, 간 기능이상, 갑상선 기능 저하증(고트리글리세라이드혈증 수반), 패혈증 등으로 인한 지방대사 이상, 심부전, 폐부전 환자

2) 세포 산소 공급 부족, 혈청 삼투압 증가
3) 전해질 보유 경향이 있는 환자

이상반응

1) 고용량, 너무 빠른 투여와 같이 부적절한 사용은 이상반응을 유발할 수 있다.
2) 체온상승, 발한, 오한, 두통, 구토, 호흡곤란이 나타날 경우 투여를 중단한다.

3) 수주 이상 지속된 장기간 비경구 영양요법시 간기능검사 수치(ALP, 트랜스아미나아제, 빌리루빈)가 일시적으로 증가할 수 있다. 간비대와 황달이 아주 드물게 나타날 수 있다.

4) 고장성 용액을 말초정맥으로 투여할 경우 혈전성 정맥염이 발생할 수 있다.

5) 이 약에 함유된 지질에 대한 대사능이 감소하였을 경우 지방 과다 증후군이 나타날 수 있는데 이는 과량 투여, 투여 시작 시, 환자의 임상상태 악화 시에도 나타난다. 지방과다 증후군은 고지혈증, 발열, 지방침착, 간 비대, 비장 비대, 빈혈, 백혈구 감소증, 혈소판 감소증, 혈액응집 이상, 혼수 등으로 특징지어질 수 있으며, 이러한 증상은 지방유제 투여를 중단 시 정상으로 돌아온다.

[간기능이상 약물 및 주의사항] [신기능이상 약물 및 주의사항]

상호작용

1) 추가하고자 하는 약물이 있을 경우 배합이 부적절할 수 있으므로 자세한 사항에 대해 제조자에게 문의한다. 배합이 적합한지를 검토하고 혼합액에 대한 안정성을 조정한다. 아주 낮은 pH 또는 2가 이온의 부적당한 용량은 지방 혼합제를 분리할 수 있다.

2) 이 약을 혈액과 동시에 투여하거나 혈액투여의 전후로 투여를 할 경우, 가응집반응의 가능성이 있기 때문에 같은 주입기구를 사용하지 않는다.

Off-label Usage

[조회]

정보요약

드럭인포 의약품 요약/상세정보

코드 및 분류정보

항목	내용
주성분코드	475400BIJ [동일한 주성분코드를 가진 오리지날 또는 제네릭 의약품 조회]
대표코드	8806466008602
BIT 약효분류	비경구영양제(Parenteral Nutritional Products)
ATC 코드	amino acids / B05BA01 [코드분류상세설명] [ATC코드예측]
복지부분류코드	325 (단백아미노산제제 )
의약품 바코드정보	내용보기 올리클리노멜엔4-550이주사/E04270482 제품규격:1500밀리리터/제품수량:1/제형:개 폼목기준코드:200511114 /대표코드:8806466008602/표준코드:8806466008619 구바코드:-/비고:-
주성분코드 분석 및 중복처방 검토	[주성분코드 분석 및 중복처방 검토]
Drugs By Indication	[전체보기]
Drugs By Classification	[전체보기]

제품정보

항목	내용
청구코드(KD코드) 비급여점검코드 상한금액	646600860[E04270482] [보험코드에 따른 약품기본정보 직접조회] \0 원/1500ml/백(2015.11.01)(최신약가) \37,400 원/1500ml/백(2014.03.01)(변경전약가) [상병코드조회] [질병코드집 다운로드]
제품성상	2개의 격막에 의해 3개의 공간으로 분리된 하나의 투명한 수액용 플라스틱 백에 A, B, C액이 각각 충전되어 있다. A액은 백색의 유화액으로서 유동성이 있는 액상 제제이고 B액과 C액은 미황색의 투명한 액제이다. [제형정보 확인]
포장·유통단위	1500ml/bag
보관방법	밀봉용기, 동결되지 않게 보관 A, B, C액 혼화 후 2-8℃에서 7일간, 25℃에서 48시간 안정하나, 개봉 및 혼화 후 즉시 사용하도록 한다
동일주성분코드 검색순위	유료정보입니다.

복약정보

항목

내용

LACTmed 바로가기

[바로가기]

약리작용

유료정보입니다.

복약지도

유료정보입니다.

임부에대한투여

*	전체임신 기간별로 여러등급이 존재할 수 있으며 가장 위험도가 높은 정보만 보여집니다. 단, 복합제의 경우 모든 복합제성분에 대한 임부투여등급이 표시된것은 절대 아니며 표시된것중에 가장 위험도가 높은 정보만 나타납니다.

FDA : C등급
(acetic acid;calcium chloride; )

*	상기 임부투여에 대한 정보는 전산처리 되면서 입력 오류 가능성이 존재합니다. 오류 가능성을 최소화하기 위하여 많은 노력을 기울이고 있으나, 그 정확성에 대하여 확신을 드릴 수 없습니다. 이에 대해 회사는 책임을 지지 않습니다.
*	반드시 공신력 있는 문헌을 다시 한번 참고 하시기 바라며 의사 또는 약사의 판단에 따라 투여여부가 결정되어야 합니다.

Pharmacokinetics

유료정보입니다.

병용금기 및 연령대금기 근거조회

[병용금기 및 연령대금기 근거조회]

보관상 주의

조제시 주의

심사정보

항목	내용
DUR 관련 고시	[병용연령금기 의약품 / 임부금기 의약품 / 비용효과적 함량 의약품 / 안전성 관련 급여중지 의약품]

학술정보

항목	내용
DUR (의약품사용평가)	병용금기 : 고시된 병용금기 내용은 없습니다. [상호작용/병용금기검색] 연령대금기 : 고시된 연령금기 내용은 없습니다. [연령대금기상세검색]
독성정보	Acetic acid에 대한 독성정보 : 정보보기 Calcium에 대한 독성정보 : 정보보기 출처: 국립독성과학원 독성물질정보DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do
Mechanism of Action	Calcium에 대한 Mechanism_Of_Action 정보 Calcium plays a vital role in the anatomy, physiology and biochemistry of organisms and of the cell, particularly in signal transduction pathways. More than 500 human proteins are known to bind or transport calcium. The skeleton acts as a major mineral storage site for the element and releases Ca2+ ions into the bloodstream under controlled conditions. Circulating calcium is either in the free, ionized form or bound to blood proteins such as serum albumin. Parathyroid hormone (secreted from the parathyroid gland) regulates the resorption of Ca2+ from bone. Calcitonin stimulates incorporation of calcium in bone, although this process is largely independent of calcitonin. Although calcium flow to and from the bone is neutral, about 5 mmol is turned over a day. Bone serves as an important storage point for calcium, as it contains 99% of the total body calcium. Low calcium intake may also be a risk factor in the development of osteoporosis. The best-absorbed form of calcium from a pill is a calcium salt like carbonate or phosphate. Calcium gluconate and calcium lactate are absorbed well by pregnant women. Seniors absorb calcium lactate, gluconate and citrate better unless they take their calcium supplement with a full breakfast. The currently recommended calcium intake is 1,500 milligrams per day for women not taking estrogen and 800 milligrams per day for women on estrogen. There is close to 300 milligrams of calcium in one cup of fluid milk. Calcium carbonate is currently the best and least expensive form of calcium supplement available. L-alanine에 대한 Mechanism_Of_Action 정보 L-Alanine is a non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and the central nervous system. BCAAs are used as a source of energy for muscle cells. During prolonged exercise, BCAAs are released from skeletal muscles and their carbon backbones are used as fuel, while their nitrogen portion is used to form another amino acid, Alanine. Alanine is then converted to Glucose by the liver. This form of energy production is called the Alanine-Glucose cycle, and it plays a major role in maintaining the body's blood sugar balance. L-arginine에 대한 Mechanism_Of_Action 정보 Many of supplemental L-arginine's activities, including its possible anti-atherogenic actions, may be accounted for by its role as the precursor to nitric oxide or NO. NO is produced by all tissues of the body and plays very important roles in the cardiovascular system, immune system and nervous system. NO is formed from L-arginine via the enzyme nitric oxide synthase or synthetase (NOS), and the effects of NO are mainly mediated by 3,'5' -cyclic guanylate or cyclic GMP. NO activates the enzyme guanylate cyclase, which catalyzes the synthesis of cyclic GMP from guanosine triphosphate or GTP. Cyclic GMP is converted to guanylic acid via the enzyme cyclic GMP phosphodiesterase. NOS is a heme-containing enzyme with some sequences similar to cytochrome P-450 reductase. Several isoforms of NOS exist, two of which are constitutive and one of which is inducible by immunological stimuli. The constitutive NOS found in the vascular endothelium is designated eNOS and that present in the brain, spinal cord and peripheral nervous system is designated nNOS. The form of NOS induced by immunological or inflammatory stimuli is known as iNOS. iNOS may be expressed constitutively in select tissues such as lung epithelium. All the nitric oxide synthases use NADPH (reduced nicotinamide adenine dinucleotide phosphate) and oxygen (O2) as cosubstrates, as well as the cofactors FAD (flavin adenine dinucleotide), FMN (flavin mononucleotide), tetrahydrobiopterin and heme. Interestingly, ascorbic acid appears to enhance NOS activity by increasing intracellular tetrahydrobiopterin. eNOS and nNOS synthesize NO in response to an increased concentration of calcium ions or in some cases in response to calcium-independent stimuli, such as shear stress. In vitro studies of NOS indicate that the Km of the enzyme for L-arginine is in the micromolar range. The concentration of L-arginine in endothelial cells, as well as in other cells, and in plasma is in the millimolar range. What this means is that, under physiological conditions, NOS is saturated with its L-arginine substrate. In other words, L-arginine would not be expected to be rate-limiting for the enzyme, and it would not appear that supraphysiological levels of L-arginine which could occur with oral supplementation of the amino acid^would make any difference with regard to NO production. The reaction would appear to have reached its maximum level. However, in vivo studies have demonstrated that, under certain conditions, e.g. hypercholesterolemia, supplemental L-arginine could enhance endothelial-dependent vasodilation and NO production. L-histidine에 대한 Mechanism_Of_Action 정보 Since the actions of supplemental L-histidine are unclear, any postulated mechanism is entirely speculative. However, some facts are known about L-histidine and some of its metabolites, such as histamine and trans-urocanic acid, which suggest that supplemental L-histidine may one day be shown to have immunomodulatory and/or antioxidant activities. Low free histidine has been found in the serum of some rheumatoid arthritis patients. Serum concentrations of other amino acids have been found to be normal in these patients. L-histidine is an excellent chelating agent for such metals as copper, iron and zinc. Copper and iron participate in a reaction (Fenton reaction) that generates potent reactive oxygen species that could be destructive to tissues, including joints. L-histidine is the obligate precursor of histamine, which is produced via the decarboxylation of the amino acid. In experimental animals, tissue histamine levels increase as the amount of dietary L-histidine increases. It is likely that this would be the case in humans as well. Histamine is known to possess immunomodulatory and antioxidant activity. Suppressor T cells have H2 receptors, and histamine activates them. Promotion of suppressor T cell activity could be beneficial in rheumatoid arthritis. Further, histamine has been shown to down-regulate the production of reactive oxygen species in phagocytic cells, such as monocytes, by binding to the H2 receptors on these cells. Decreased reactive oxygen species production by phagocytes could play antioxidant, anti-inflammatory and immunomodulatory roles in such diseases as rheumatoid arthritis. This latter mechanism is the rationale for the use of histamine itself in several clinical trials studying histamine for the treatment of certain types of cancer and viral diseases. In these trials, down-regulation by histamine of reactive oxygen species formation appears to inhibit the suppression of natural killer (NK) cells and cytotoxic T lymphocytes, allowing these cells to be more effective in attacking cancer cells and virally infected cells. L-isoleucine에 대한 Mechanism_Of_Action 정보 (Applies to Valine, Leucine and Isoleucine) This group of essential amino acids are identified as the branched-chain amino acids, BCAAs. Because this arrangement of carbon atoms cannot be made by humans, these amino acids are an essential element in the diet. The catabolism of all three compounds initiates in muscle and yields NADH and FADH2 which can be utilized for ATP generation. The catabolism of all three of these amino acids uses the same enzymes in the first two steps. The first step in each case is a transamination using a single BCAA aminotransferase, with a-ketoglutarate as amine acceptor. As a result, three different a-keto acids are produced and are oxidized using a common branched-chain a-keto acid dehydrogenase, yielding the three different CoA derivatives. Subsequently the metabolic pathways diverge, producing many intermediates. The principal product from valine is propionylCoA, the glucogenic precursor of succinyl-CoA. Isoleucine catabolism terminates with production of acetylCoA and propionylCoA; thus isoleucine is both glucogenic and ketogenic. Leucine gives rise to acetylCoA and acetoacetylCoA, and is thus classified as strictly ketogenic. There are a number of genetic diseases associated with faulty catabolism of the BCAAs. The most common defect is in the branched-chain a-keto acid dehydrogenase. Since there is only one dehydrogenase enzyme for all three amino acids, all three a-keto acids accumulate and are excreted in the urine. The disease is known as Maple syrup urine disease because of the characteristic odor of the urine in afflicted individuals. Mental retardation in these cases is extensive. Unfortunately, since these are essential amino acids, they cannot be heavily restricted in the diet; ultimately, the life of afflicted individuals is short and development is abnormal The main neurological problems are due to poor formation of myelin in the CNS. L-leucine에 대한 Mechanism_Of_Action 정보 This group of essential amino acids are identified as the branched-chain amino acids, BCAAs. Because this arrangement of carbon atoms cannot be made by humans, these amino acids are an essential element in the diet. The catabolism of all three compounds initiates in muscle and yields NADH and FADH2 which can be utilized for ATP generation. The catabolism of all three of these amino acids uses the same enzymes in the first two steps. The first step in each case is a transamination using a single BCAA aminotransferase, with a-ketoglutarate as amine acceptor. As a result, three different a-keto acids are produced and are oxidized using a common branched-chain a-keto acid dehydrogenase, yielding the three different CoA derivatives. Subsequently the metabolic pathways diverge, producing many intermediates. The principal product from valine is propionylCoA, the glucogenic precursor of succinyl-CoA. Isoleucine catabolism terminates with production of acetylCoA and propionylCoA; thus isoleucine is both glucogenic and ketogenic. Leucine gives rise to acetylCoA and acetoacetylCoA, and is thus classified as strictly ketogenic. There are a number of genetic diseases associated with faulty catabolism of the BCAAs. The most common defect is in the branched-chain a-keto acid dehydrogenase. Since there is only one dehydrogenase enzyme for all three amino acids, all three a-keto acids accumulate and are excreted in the urine. The disease is known as Maple syrup urine disease because of the characteristic odor of the urine in afflicted individuals. Mental retardation in these cases is extensive. Unfortunately, since these are essential amino acids, they cannot be heavily restricted in the diet; ultimately, the life of afflicted individuals is short and development is abnormal The main neurological problems are due to poor formation of myelin in the CNS. L-lysine에 대한 Mechanism_Of_Action 정보 Proteins of the herpes simplex virus are rich in L-arginine, and tissue culture studies indicate an enhancing effect on viral replication when the amino acid ratio of L-arginine to L-lysine is high in the tissue culture media. When the ratio of L-lysine to L-arginine is high, viral replication and the cytopathogenicity of herpes simplex virus have been found to be inhibited. L-lysine may facilitate the absorption of calcium from the small intestine. L-methionine에 대한 Mechanism_Of_Action 정보 The mechanism of the possible anti-hepatotoxic activity of L-methionine is not entirely clear. It is thought that metabolism of high doses of acetaminophen in the liver lead to decreased levels of hepatic glutathione and increased oxidative stress. L-methionine is a precursor to L-cysteine. L-cysteine itself may have antioxidant activity. L-cysteine is also a precursor to the antioxidant glutathione. Antioxidant activity of L-methionine and metabolites of L-methionine appear to account for its possible anti-hepatotoxic activity. Recent research suggests that methionine itself has free-radical scavenging activity by virtue of its sulfur, as well as its chelating ability. L-phenylalanine에 대한 Mechanism_Of_Action 정보 The mechanism of L-phenylalanine's putative antidepressant activity may be accounted for by its precursor role in the synthesis of the neurotransmitters norepinephrine and dopamine. Elevated brain norepinephrine and dopamine levels are thought to be associated with antidepressant effects. The mechanism of L-phenylalanine's possible antivitiligo activity is not well understood. It is thought that L-phenylalanine may stimulate the production of melanin in the affected skin L-proline에 대한 Mechanism_Of_Action 정보 Glycogenic, by L-Proline oxidase in the kidney, it is ring-opened and is oxidized to form L-Glutamic acid. L-Ornithine and L-Glutamic acid are converted to L-Proline via L-Glutamic acid-gamma-semialdehyde. It is contained abundantly in collagen, and is intimately involved in the function of arthrosis and chordae.
Pharmacology	L-alanine에 대한 Pharmacology 정보 Is an important source of energy for muscle tissue, the brain and central nervous system; strengthens the immune system by producing antibodies; helps in the metabolism of sugars and organic acids. L-arginine에 대한 Pharmacology 정보 Studies have shown that is has improved immune responses to bacteria, viruses and tumor cells; promotes wound healing and regeneration of the liver; causes the release of growth hormones; considered crucial for optimal muscle growth and tissue repair. L-histidine에 대한 Pharmacology 정보 Is found abundantly in hemoglobin; has been used in the treatment of rheumatoid arthritis, allergic diseases, ulcers and anemia. A deficiency can cause poor hearing. L-isoleucine에 대한 Pharmacology 정보 They provide ingredients for the manufacturing of other essential biochemical components in the body, some of which are utilized for the production of energy, stimulants to the upper brain and helping you to be more alert. L-leucine에 대한 Pharmacology 정보 An essential amino acid. (Claim) Leucine helps with the regulation of blood-sugar levels, the growth and repair of muscle tissue (such as bones, skin and muscles), growth hormone production, wound healing as well as energy regulation. It can assist to prevent the breakdown of muscle proteins that sometimes occur after trauma or severe stress. It may also be beneficial for individuals with phenylketonuria - a condition in which the body cannot metabolize the amino acid phenylalanine L-lysine에 대한 Pharmacology 정보 Insures the adequate absorption of calcium; helps form collagen ( which makes up bone cartilage & connective tissues); aids in the production of antibodies, hormones & enzymes. Recent studies have shown that Lysine may be effective against herpes by improving the balance of nutrients that reduce viral growth. A deficiency may result in tiredness, inability to concentrate, irritability, bloodshot eyes, retarded growth, hair loss, anemia & reproductive problems. L-methionine에 대한 Pharmacology 정보 L-Methionine is a principle supplier of sulfur which prevents disorders of the hair, skin and nails; helps lower cholesterol levels by increasing the liver's production of lecithin; reduces liver fat and protects the kidneys; a natural chelating agent for heavy metals; regulates the formation of ammonia and creates ammonia-free urine which reduces bladder irritation; influences hair follicles and promotes hair growth. L-methionine may protect against the toxic effects of hepatotoxins, such as acetaminophen. Methionine may have antioxidant activity. L-phenylalanine에 대한 Pharmacology 정보 Used by the brain to produce Norepinephrine, a chemical that transmits signals between nerve cells and the brain; keeps you awake and alert; reduces hunger pains; functions as an antidepressant and helps improve memory. L-proline에 대한 Pharmacology 정보 L-Proline is a major amino acid found in cartilage and is important for maintaining youthful skin as well as repair of muscle, connective tissue and skin damage. It is also essential for the immune system, and for necessary balance of this formula. It is an essential component of collagen and is important for proper functioning of joints and tendons. L-Proline is extremely important for the proper functioning of joints and tendons. Helps maintain and strengthen heart muscles.
Absorption	L-arginine에 대한 Absorption 정보 Absorbed from the lumen of the small intestine into the enterocytes. Absorption is efficient and occurs by an active transport mechanism. L-histidine에 대한 Absorption 정보 Absorbed from the small intestine via an active transport mechanism requiring the presence of sodium. L-isoleucine에 대한 Absorption 정보 Absorbed from the small intestine by a sodium-dependent active-transport process L-lysine에 대한 Absorption 정보 Absorbed from the lumen of the small intestine into the enterocytes by an active transport process L-methionine에 대한 Absorption 정보 Absorbed from the lumen of the small intestine into the enterocytes by an active transport process. L-phenylalanine에 대한 Absorption 정보 Absorbed from the small intestine by a sodium dependent active transport process.
Pharmacokinetics	Glucose monohydrate의 약물동력학자료 흡수 : 경구투여 10-20분 후에 위장관에서 빠르게 흡수되어 투여후 40분경에 최고 혈중농도를 나타낸다. 분포 : monosaccharide glucose 의 형태로 분포,저장된다. 대사되어 물,이산화탄소,에너지를 방출한다. L-arginine의 약물동력학자료 최고 혈중농도 도달 : 경구 : 2시간 최대 효과 발현 : 당뇨 진단 : 정맥주사 : 20-45 분 혈당의 최고 상승은 20분 후에 나타나며, 인슐린의 최대 상승은 20-30 분 후에 나타나며 glucagon은 30-45 분 후에 나타난다. 성장호르몬 보유 진단 : 정맥주사 : 1-2 시간 Arginine 30 g을 30분간 정맥주사 후 성장호르몬의 최대 상승이 약 1-2 시간 후에 나타난다. 작용 지속 시간 : 정맥주사 : 1시간 흡수 : 위장관에서 잘 흡수됨 대사 : 간에서 arginase에 의해 guanidino group이 가수분해되어 urea와 ornithine을 생성한다. Ornithine은 궁극적으로 glucose 생성에 이용된다. 소실 : 신장 : 사구체로 여과되고 신세뇨관으로 재흡수된다. 반감기 : 1.2-2 시간 Aminoacetic Acid(Glycine)의 약물동력학자료 대사 : Glycine은 단백, creatinine, glycocholic acid, glutathione, uric acid, heme 등의 합성에 관여한다. 체내에서의 분해는 여러단계로 이루어지며 주된 경로는 가역적인 산화적 분해이다. Serine이 정상적인 분해산물이다. 혈장 반감기 : 85분 Potassium Chloride의 약물동력학자료 흡수 : 상부 위장관에서 잘 흡수됨 분포 : 세포외액에서 능동수송에 의해 세포내로 들어감 소실 : 주로 뇨배설, 소량이 피부, 대변으로 배설되며, 대변으로 배설된 것은 다시 재흡수됨 Sodium acetate trihydrate의 약물동력학자료 대사 : 중탄산 (bicarbonate) 이온으로의 대사는 간 이외의 부위에서 이루어진다. Calcium chloride dihydrate의 약물동력학자료 흡수 : 정맥 칼슘염은 직접 혈류로 유입된다. 분포 : 태반통과 유즙분비 L-methionine의 약물동력학자료 대사 : S-adenosylmethionine을 거쳐 homocysteine으로 전환된다. 그 후 80%가 cystathione, cysteine, taurine, inorganic sulphate로 점차로 대사된다. Magnesium chloride hexahydrate의 약물동력학자료 흡수 : 복용량의 ⅓-½이 소장에서 서서히 흡수된다. 단백결합 : 약 25-30% 소실 : 흡수된 양의 90% 이상이 신배설된다.
Toxicity	L-arginine에 대한 Toxicity 정보 Oral supplementation with L-arginine at doses up to 15 grams daily are generally well tolerated. The most common adverse reactions of higher doses from 15 to 30 grams daily are nausea, abdominal cramps and diarrhea. Some may experience these symptoms at lower doses. L-histidine에 대한 Toxicity 정보 ORL-RAT LD₅₀ > 15000 mg/kg, IPR-RAT LD₅₀ > 8000 mg/kg, ORL-MUS LD₅₀ > 15000 mg/kg, IVN-MUS LD₅₀ > 2000 mg/kg; Mild gastrointestinal side effects. L-isoleucine에 대한 Toxicity 정보 Symptoms of hypoglycemia, increased mortality in ALS patients taking large doses of BCAAs L-lysine에 대한 Toxicity 정보 Not Available L-methionine에 대한 Toxicity 정보 Doses of L-methionine of up to 250 mg daily are generally well tolerated. Higher doses may cause nausea, vomiting and headache. Healthy adults taking 8 grams of L-methionine daily for four days were found to have reduced serum folate levels and leucocytosis. Healthy adults taking 13.9 grams of L-methionine daily for five days were found to have changes in serum pH and potassium and increased urinary calcium excretion. Schizophrenic patients given 10 to 20 grams of L-methionine daily for two weeks developed functional psychoses. Single doses of 8 grams precipitated encephalopathy in patients with cirrhosis. L-phenylalanine에 대한 Toxicity 정보 L-phenylalanine will exacerbate symptoms of phenylketonuria if used by phenylketonurics. L-phenylalanine was reported to exacerbate tardive dyskinesia when used by some with schizophrenia. L-proline에 대한 Toxicity 정보 Not Available
Drug Interactions	Calcium에 대한 Drug_Interactions 정보 Alendronate Formation of non-absorbable complexesAmprenavir The antiacid decreases the absorption of amprenavirAtazanavir This gastric pH modifier decreases the levels/effects of atazanavirChloroquine The antiacid decreases the absorption of chloroquineCiprofloxacin Formation of non-absorbable complexesDapsone Formation of non-absorbable complexesDelavirdine The antiacid decreases the effect of delavirdineDemeclocycline Formation of non-absorbable complexesDoxycycline Formation of non-absorbable complexesEnoxacin Formation of non-absorbable complexesFosamprenavir The antiacid decreases the absorption of amprenavirGrepafloxacin Formation of non-absorbable complexesIbandronate Formation of non-absorbable complexesIndinavir The antiacid decreases the absorption of indinavirItraconazole The antacid decreases the effect of the imidazoleKetoconazole The antacid decreases the effect of the imidazoleLevofloxacin Formation of non-absorbable complexesLevothyroxine Calcium decreases absorption of levothyroxineLomefloxacin Formation of non-absorbable complexesMethacycline Formation of non-absorbable complexesMinocycline Formation of non-absorbable complexesMoxifloxacin Formation of non-absorbable complexesNorfloxacin Formation of non-absorbable complexesOfloxacin Formation of non-absorbable complexesOxytetracycline Formation of non-absorbable complexesPefloxacin Formation of non-absorbable complexesPolystyrene sulfonate Formation of non-absorbable complexesRisedronate Formation of non-absorbable complexesTetracycline Formation of non-absorbable complexesTrovafloxacin Formation of non-absorbable complexesClodronate Formation of non-absorbable complexesEtidronic acid Formation of non-absorbable complexesMycophenolate mofetil Formation of non-absorbable complexesTemafloxacin Formation of non-absorbable complexes L-arginine에 대한 Drug_Interactions 정보 Not Available L-histidine에 대한 Drug_Interactions 정보 Not Available L-isoleucine에 대한 Drug_Interactions 정보 Not Available L-lysine에 대한 Drug_Interactions 정보 Not Available L-methionine에 대한 Drug_Interactions 정보 Not Available L-phenylalanine에 대한 Drug_Interactions 정보 Not Available L-proline에 대한 Drug_Interactions 정보 Not Available
CYP450 Drug Interaction	[CYP450 Table직접조회]
Drug Target	[Drug Target]
Description	Calcium에 대한 Description 정보 Calcium plays a vital role in the anatomy, physiology and biochemistry of organisms and of the cell, particularly in signal transduction pathways. The skeleton acts as a major mineral storage site for the element and releases Ca2+ ions into the bloodstream under controlled conditions. Circulating calcium is either in the free, ionized form or bound to blood proteins such as serum albumin. Although calcium flow to and from the bone is neutral, about 5 mmol is turned over a day. Bone serves as an important storage point for calcium, as it contains 99% of the total body calcium. Low calcium intake may also be a risk factor in the development of osteoporosis. The best-absorbed form of calcium from a pill is a calcium salt like carbonate or phosphate. Calcium gluconate and calcium lactate are absorbed well by pregnant women. Seniors absorb calcium lactate, gluconate and citrate better unless they take their calcium supplement with a full breakfast. L-alanine에 대한 Description 정보 A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and the central nervous system. [PubChem] L-arginine에 대한 Description 정보 An essential amino acid that is physiologically active in the L-form. [PubChem] L-histidine에 대한 Description 정보 An essential amino acid that is required for the production of histamine. [PubChem] L-isoleucine에 대한 Description 정보 An essential branched-chain aliphatic amino acid found in many proteins. It is an isomer of leucine. It is important in hemoglobin synthesis and regulation of blood sugar and energy levels. [PubChem] L-leucine에 대한 Description 정보 An essential branched-chain amino acid important for hemoglobin formation. [PubChem] L-lysine에 대한 Description 정보 L-Lysine (abbreviated as Lys or K)[1] is an 慣-amino acid with the chemical formula HO2CCH(NH2)(CH2)4NH2. This amino acid is an essential amino acid, which means that humans cannot synthesize it. Its codons are AAA and AAG.L-Lysine is a base, as are arginine and histidine. The 琯-amino group often participates in hydrogen bonding and as a general base in catalysis. Common posttranslational modifications include methylation of the 琯-amino group, giving methyl-, dimethyl-, and trimethyllysine. The latter occurs in calmodulin. Other posttranslational modifications include acetylation. Collagen contains hydroxylysine which is derived from lysine by lysyl hydroxylase. O-Glycosylation of lysine residues in the endoplasmic reticulum or Golgi apparatus is used to mark certain proteins for secretion from the cell. L-methionine에 대한 Description 정보 A sulfur containing essential amino acid that is important in many body functions. It is a chelating agent for heavy metals. [PubChem] L-phenylalanine에 대한 Description 정보 An essential aromatic amino acid that is a precursor of melanin; dopamine; noradrenalin (norepinephrine), and thyroxine. [PubChem] L-proline에 대한 Description 정보 A non-essential amino acid that is synthesized from glutamic acid. It is an essential component of collagen and is important for proper functioning of joints and tendons. [PubChem]
Dosage Form	Calcium에 대한 Dosage_Form 정보 Capsule OralLiquid DentalLiquid IntravenousLiquid OralLiquid SublingualPaste DentalPowder OralPowder, for solution OralSolution IntramuscularSolution IntravenousSolution OralSolution / drops OralSyrup OralTablet OralTablet, chewable Oral L-alanine에 대한 Dosage_Form 정보 Not Available L-arginine에 대한 Dosage_Form 정보 Liquid Intravenous L-histidine에 대한 Dosage_Form 정보 Capsule OralPowder OralTablet Oral L-isoleucine에 대한 Dosage_Form 정보 Capsule OralPowder OralTablet Oral L-leucine에 대한 Dosage_Form 정보 Capsule OralPowder OralTablet Oral L-lysine에 대한 Dosage_Form 정보 Not Available L-methionine에 대한 Dosage_Form 정보 Capsule OralPowder OralTablet OralTablet Oral
Drug Category	L-alanine에 대한 Drug_Category 정보 Dietary supplementMicronutrientNon-Essential Amino Acids L-arginine에 대한 Drug_Category 정보 Conditionally Essential Amino AcidsDietary supplementMicronutrient L-histidine에 대한 Drug_Category 정보 Conditionally Essential Amino AcidsDietary supplementMicronutrient L-isoleucine에 대한 Drug_Category 정보 Dietary supplementEssential Amino AcidsMicronutrient L-leucine에 대한 Drug_Category 정보 Dietary supplementEssential Amino AcidsMicronutrient L-lysine에 대한 Drug_Category 정보 Dietary supplementEssential Amino AcidsMicronutrient L-methionine에 대한 Drug_Category 정보 Dietary supplementEssential Amino AcidsMicronutrient L-phenylalanine에 대한 Drug_Category 정보 Dietary supplementEssential Amino AcidsMicronutrient L-proline에 대한 Drug_Category 정보 Dietary supplementMicronutrientNon-Essential Amino Acids
Smiles String Canonical	Calcium에 대한 Smiles_String_canonical 정보 Not Available L-alanine에 대한 Smiles_String_canonical 정보 CC(N)C(O)=O L-arginine에 대한 Smiles_String_canonical 정보 NC(CCCN=C(N)N)C(O)=O L-histidine에 대한 Smiles_String_canonical 정보 NC(CC1=CN=CN1)C(O)=O L-isoleucine에 대한 Smiles_String_canonical 정보 CCC(C)C(N)C(O)=O L-leucine에 대한 Smiles_String_canonical 정보 CC(C)CC(N)C(O)=O L-lysine에 대한 Smiles_String_canonical 정보 NCCCCC(N)C(O)=O L-methionine에 대한 Smiles_String_canonical 정보 CSCCC(N)C(O)=O L-phenylalanine에 대한 Smiles_String_canonical 정보 NC(CC1=CC=CC=C1)C(O)=O L-proline에 대한 Smiles_String_canonical 정보 OC(=O)C1CCCN1
Smiles String Isomeric	Calcium에 대한 Smiles_String_isomeric 정보 Not Available L-alanine에 대한 Smiles_String_isomeric 정보 C[C@H](N)C(O)=O L-arginine에 대한 Smiles_String_isomeric 정보 N[C@@H](CCC\N=C(\N)N)C(O)=O L-histidine에 대한 Smiles_String_isomeric 정보 N[C@@H](CC1=CN=CN1)C(O)=O L-isoleucine에 대한 Smiles_String_isomeric 정보 CC[C@H](C)[C@H](N)C(O)=O L-leucine에 대한 Smiles_String_isomeric 정보 CC(C)C[C@@H](N)C(O)=O L-lysine에 대한 Smiles_String_isomeric 정보 NCCCC[C@H](N)C(O)=O L-methionine에 대한 Smiles_String_isomeric 정보 CSCC[C@H](N)C(O)=O L-phenylalanine에 대한 Smiles_String_isomeric 정보 N[C@@H](CC1=CC=CC=C1)C(O)=O L-proline에 대한 Smiles_String_isomeric 정보 OC(=O)[C@@H]1CCCN1
InChI Identifier	Calcium에 대한 InChI_Identifier 정보 Not Available L-alanine에 대한 InChI_Identifier 정보 InChI=1/C3H7NO2/c1-2(4)3(5)6/h2H,4H2,1H3,(H,5,6)/t2-/m0/s1/f/h5H L-arginine에 대한 InChI_Identifier 정보 InChI=1/C6H14N4O2/c7-4(5(11)12)2-1-3-10-6(8)9/h4H,1-3,7H2,(H,11,12)(H4,8,9,10)/t4-/m0/s1/f/h11H,8-9H2 L-histidine에 대한 InChI_Identifier 정보 InChI=1/C6H9N3O2/c7-5(6(10)11)1-4-2-8-3-9-4/h2-3,5H,1,7H2,(H,8,9)(H,10,11)/t5-/m0/s1/f/h9-10H L-isoleucine에 대한 InChI_Identifier 정보 InChI=1/C6H13NO2/c1-3-4(2)5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/t4-,5-/m0/s1/f/h8H L-leucine에 대한 InChI_Identifier 정보 InChI=1/C6H13NO2/c1-4(2)3-5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/f/h8H L-lysine에 대한 InChI_Identifier 정보 InChI=1/C6H14N2O2/c7-4-2-1-3-5(8)6(9)10/h5H,1-4,7-8H2,(H,9,10)/t5-/m0/s1/f/h9H L-methionine에 대한 InChI_Identifier 정보 InChI=1/C5H11NO2S/c1-9-3-2-4(6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8)/t4-/m0/s1/f/h7H L-phenylalanine에 대한 InChI_Identifier 정보 InChI=1/C9H11NO2/c10-8(9(11)12)6-7-4-2-1-3-5-7/h1-5,8H,6,10H2,(H,11,12)/t8-/m0/s1/f/h11H L-proline에 대한 InChI_Identifier 정보 InChI=1/C5H9NO2/c7-5(8)4-2-1-3-6-4/h4,6H,1-3H2,(H,7,8)/t4-/m0/s1/f/h7H
Chemical IUPAC Name	Calcium에 대한 Chemical_IUPAC_Name 정보 Not Available L-alanine에 대한 Chemical_IUPAC_Name 정보 (2S)-2-aminopropanoic acid L-arginine에 대한 Chemical_IUPAC_Name 정보 (2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid L-histidine에 대한 Chemical_IUPAC_Name 정보 (2S)-2-amino-3-(3H-imidazol-4-yl)propanoic acid L-isoleucine에 대한 Chemical_IUPAC_Name 정보 (2S,3S)-2-amino-3-methylpentanoic acid L-leucine에 대한 Chemical_IUPAC_Name 정보 2-amino-4-methylpentanoic acid L-lysine에 대한 Chemical_IUPAC_Name 정보 (2S)-2,6-diaminohexanoic acid L-methionine에 대한 Chemical_IUPAC_Name 정보 (2S)-2-amino-4-methylsulfanylbutanoic acid L-phenylalanine에 대한 Chemical_IUPAC_Name 정보 (2S)-2-amino-3-phenylpropanoic acid L-proline에 대한 Chemical_IUPAC_Name 정보 (2S)-pyrrolidine-2-carboxylic acid
Drug-Induced Toxicity Related Proteins	LYSINE 의 Drug-Induced Toxicity Related Protein정보 Replated Protein:Tamm-Horsfall protein Drug:Lysine Toxicity:persisting acute renal failure . [바로가기] METHIONINE 의 Drug-Induced Toxicity Related Protein정보 Replated Protein:NMDA receptor-regulated protein Drug:methionine Toxicity:cerebrovascular disease. [바로가기] Replated Protein:Cystathionine beta-synthase Drug:methionine Toxicity:lipoprotein peroxidation and platelet aggregation. [바로가기] Replated Protein:Methylenetetrahydrofolate reductase Drug:methionine Toxicity:lipoprotein peroxidation and platelet aggregation. [바로가기]

사용자컨텐츠

항목

내용

핵심 요약 정보